Top

Journal of Hepato-Biliary-Pancreatic Sciences

Published in:

Open Access 01-03-2013 | Original article

Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases

Authors: Yuko Takami, Tomoki Ryu, Yoshiyuki Wada, Hideki Saitsu

Published in: Journal of Hepato-Biliary-Pancreatic Sciences | Issue 3/2013

Abstract

Background

Hepatic resection (HRx) or radiofrequency ablation may be carried out as the first-line treatment of hepatocellular carcinoma (HCC). However, we have used intraoperative microwave ablation, named microwave coagulo-necrotic therapy (MCN) as part of our strategy for the treatment of HCCs for more than 15 years. Here we describe the treatment outcomes achieved at our institution as a high-volume center for microwave ablation.

Methods

Between July 1994 and December 2010, 719 consecutive patients received MCN as their initial therapy for HCC (mean tumor size 26.9 mm, mean number of lesions 2.51) at our institute. The therapeutic survival effect, local tumor progression, and overall recurrence were prospectively evaluated and statistically analyzed.

Results

The 1-, 3-, 5-, 7-, and 10-year overall survival rates of all 719 patients were 97.7, 79.8, 62.1, 45.3, and 34.1 %, respectively. Thirty percent of the patients had Child–Pugh class B cirrhosis and the 5-year survival rate of these patients was 46.6 %. The 5-year survival of patients with ≥4 lesions (n = 168) was 49.6 % and that of patients meeting the Milan criteria (n = 470) was 70.9 %. The 1-, 3-, 5-, 7-, and 10-year overall survival rates for 390 patients treated with MCN who had ≤3 lesions with diameter ≤3 cm were 97.9, 85.1, 70.0, 57.1, and 43.0 %. No significant differences were found between the overall survival rates after MCN and the overall survival rates in 34 patients treated with HRx during the same period at our institute and under the same (P = 0.3592), nor were there any differences in disease-free survival (P = 0.3496) and local recurrence rates between the MCN and HRx groups (P = 0.5926).

Conclusion

MCN is effective for the locoregional control of HCC, with results comparable to those of HRx. MCN should be considered as one of the first-choice treatments for HCC, even for patients with poor liver function or multiple lesions.

Takayama T, Makuuchi M, Hirohashi S, Sakamoto M. Early hepatocellular carcinoma as an entity with a high cure rate of surgical cure. Hepatology. 1998;28:1241–6.PubMedCrossRef

Majima Y, Tanikawa K. Percutaneous ethanol injection therapy (PEIT) for small hepatocellular carcinoma smaller than 30 mm in diameter. Jpn J Med Ultrasonics. 1991;18:S41–2.

Pearson AS, Izzo F, Fleming RYD, Ellis LM, Delrio P, Roh MS, et al. Intraoperative radiofrequency ablation or cryoablation for hepatic malignancies. Am J Surg. 1999;178:592–8.PubMedCrossRef

Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazalle GF. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210:655–61.PubMed

Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103:1201–9.PubMedCrossRef

N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrie N, Grando V, Coderc E, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 western patients with cirrhosis. Hepatology. 2009;50:1475–83.PubMedCrossRef

Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli G, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–9.PubMedCrossRef

Tabuse K. A new operative procedure of hepatic surgery using a microwave tissue coagulator. Arch Jpn Chir. 1979;48:160–72.

Saitsu H, Yoshida M, Taniwaki S, Sato H, Okami N, Okuda Y, et al. Laparoscopic coagulo-necrotic therapy using Microtase for small hepatocellular carcinoma. Jpn J Gastroenterol. 1991;88:2727.

10.

Seki T, Wakabayashi M, Nakagawa T, Imamura M, Tamai T, Nishimura A, et al. Percutaneous microwave coagulation therapy for patients with small hepatocellular carcinoma. Cancer. 1999;85:1694–702.PubMedCrossRef

11.

Rossi S, Di Stasi M, Buscarini E, Cavanna L, Quaretti P, Squassante E, et al. Percutaneous radio frequency interstitial thermal ablation in the treatment of small hepatocellular carcinoma. Cancer J Sci Am. 1995;1:73–81.PubMed

12.

Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 2002;223:331–7.PubMedCrossRef

13.

Liang P, Wang Y. Microwave ablation of hepatocellular carcinoma. Oncology. 2007;72:124–31.PubMedCrossRef

14.

Liang P, Dong B, Yu X, Yu D, Wang Y, Feng L, et al. Prognostic factors for survival in patients with hepatocellular carcinoma after percutaneous microwave ablation. Radiology. 2005;235:299–307.PubMedCrossRef

15.

Martin RCG, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol. 2010;17:171–8.PubMedCrossRef

16.

Bhardwaj N, Strickland A, Ahmed F, El-Abassy M, Morgan B, Robertson GSM, et al. Microwave ablation for unresectable hepatic tumours: clinical results using a novel microwave probe and generator. Eur J Surg Oncol. 2010;36:264–8.PubMedCrossRef

17.

Skinner MG, Iizuka MN, Kolios MC, Sherar MD. A theoretical comparison of energy sources—microwave, ultrasound and laser—for interstitial thermal therapy. Phys Med Biol. 1998;43:3535–47.PubMedCrossRef

18.

Wright AS, Sampson LA, Warner TF, Mahvi AM, Lee FT. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology. 2005;236:132–9.PubMedCrossRef

19.

Takada Y, Kurata M, Ohkohchi N. Rapid and aggressive recurrence accompanied by portal tumor thrombus after radiofrequency ablation for hepatocellular carcinoma. Int J Clin Oncol. 2003;8:332–5.PubMedCrossRef

20.

Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001;33:1124–9.PubMedCrossRef

21.

Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, et al. Rapid progression of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol. 2004;10:1137–40.PubMed

22.

Kotoh K, Morizono S, Kohjima M, Enjoji M, Sakai H, Nakamuta M. Evaluation of liver parenchymal pressure and portal endothelium damage during radio frequency ablation in an in vivo porcine model. Liver Int. 2005;25:1217–23.PubMedCrossRef

23.

Kawamoto C, Yamauchi A, Baba Y, Kaneko K, Yakabi K. Measurement of intrahepatic pressure during radiofrequency ablation in porcine liver. J Gastroenterol. 2010;45:435–42.PubMedCrossRef

24.

Okusaka T, Okada S, Ueno H, Ikeda M, Shimada K, Yamamoto J, et al. Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features. Cancer. 2002;95:1931–7.PubMedCrossRef

25.

Wright AS, Lee FT, Mahvi DM. Hepatic microwave ablation with multiple antennae results in synergistically larger zones of coagulation necrosis. Ann Surg Oncol. 2003;10:275–83.PubMedCrossRef

26.

Simon CJ, Dupuy DE, Iannitti DA, Lu DSK, Yu NC, Asward BI, et al. Intraoperative triple antenna hepatic microwave ablation. AJR Am J Roentgenol. 2007;187:W333–40.CrossRef

27.

Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–40.PubMedCrossRef

28.

Ikeda M, Okada S, Ueno H, Okusaka T, Kuriyama H. Radiofrequency ablation and percutaneous ethanol injection in patients with small hepatocellular carcinoma: a comparative study. Jpn J Clin Oncol. 2001;31:322–6.PubMedCrossRef

29.

Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003;38:207–15.PubMedCrossRef

30.

Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology. 2006;131:461–9.PubMedCrossRef

31.

Liang P, Wang Y, Yu X, Dong B. Malignant liver tumors: treatment with percutaneous microwave ablation—complications among cohort of 1136 patients. Radiology. 2009;251:933–40.PubMedCrossRef

Title: Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases
Authors: Yuko Takami
Tomoki Ryu
Yoshiyuki Wada
Hideki Saitsu
Publication date: 01-03-2013
Publisher: Springer Japan
Published in: Journal of Hepato-Biliary-Pancreatic Sciences / Issue 3/2013
Print ISSN: 1868-6974
Electronic ISSN: 1868-6982
DOI: https://doi.org/10.1007/s00534-012-0527-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2013

Living donor liver transplantation for patients immunized against human leukocyte antigen

The clinical role of critical pathway implementation for pancreaticoduodenectomy in 179 patients

Early DNA damage response in residual carcinoma in situ at ductal stumps and local recurrence in patients undergoing resection for extrahepatic cholangiocarcinoma

Newsletter, March 1, 2013

Surgical treatment of perihilar cholangiocarcinoma in octogenarians: a single center experience

Changes in the therapeutic strategy for acute cholecystitis after the Tokyo guidelines were published